Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q2 2025 (← Previous) (Next →)

Filing Date: Aug 11, 2025

Total Value ($000): $82,137 (100.0% shares, 0.0% debt)

Holdings (8)

GLUE Monte Rosa Therapeutics, Inc. 31.0%

Value ($000) $25,495 Shares 5,652,922 Est. Cost $7.50 Unrealized -40.6%

CRSP CRISPR Therapeutics AG 29.5%

Value ($000) $24,250 Shares 498,558 Est. Cost $40.26 Unrealized -3.9%

JBIO Jade Biosciences, Inc. 18.6%

Value ($000) $15,243 Shares 1,525,820 Est. Cost $33.31 Unrealized 0.0%

SKYE Skye Bioscience, Inc. 10.2%

Value ($000) $8,392 Shares 2,007,704 Est. Cost $7.75 Unrealized -73.3%

— Repare Therapeutics, Inc. 4.5%

Value ($000) $3,679 Shares 2,646,657 Est. Cost $10.58 Unrealized —

CTNM Contineum Therapeutics, Inc. 2.6%

Value ($000) $2,154 Shares 542,628 Est. Cost $16.10 Unrealized -73.0%

— Tempest Therapeutics, Inc. 2.2%

Value ($000) $1,834 Shares 269,772 Est. Cost $6.80 Unrealized —

— Adverum Biotechnologies, Inc. 1.3%

Value ($000) $1,090 Shares 506,821 Est. Cost $9646.10 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
GLUE	Monte Rosa Therapeutics, Inc.	5,652,922	$25,495	31.0%	$7.50	-40.6%	Common Stock	61225M102
CRSP	CRISPR Therapeutics AG	498,558	$24,250	29.5%	$40.26	-3.9%	Common Shares	H17182108
JBIO	Jade Biosciences, Inc.	1,525,820	$15,243	18.6%	$33.31	0.0%	Common Stock	008064206
SKYE	Skye Bioscience, Inc.	2,007,704	$8,392	10.2%	$7.75	-73.3%	Common Stock	83086J200
—	Repare Therapeutics, Inc.	2,646,657	$3,679	4.5%	$10.58	—	Common Stock	760273102
CTNM	Contineum Therapeutics, Inc.	542,628	$2,154	2.6%	$16.10	-73.0%	Common Stock	21217B100
—	Tempest Therapeutics, Inc.	269,772	$1,834	2.2%	$6.80	—	Common Stock	87978U108
—	Adverum Biotechnologies, Inc.	506,821	$1,090	1.3%	$9646.10	—	Common Stock	00773U108